B Cell News and Research

RSS

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases confirmed that testing of two (2) of the company's compounds Onconase (Ranpirnase), and recombinant Amphinase 2 showed positive in vitro results for Severe Acute Respiratory Syndrome, also known as (SARS) virus.

22 Jul 2010

Study links application of disinfectants in recreational pools to adverse health outcomes

Splashing around in a swimming pool on a hot summer day may not be as safe as you think. A recent University of Illinois study links the application of disinfectants in recreational pools to previously published adverse health outcomes such as asthma and bladder cancer.

22 Jul 2010

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010. The Company reported total revenue of $164.4 million for the quarter ended June 30, 2010, which includes net product sales of $162.5 million. Net loss, excluding a restructuring charge of $3.4 million, was $40.8 million, or $0.28 per share.

22 Jul 2010

Valproic acid halts vision loss in patients with retinitis pigmentosa

Researchers at the University of Massachusetts Medical School believe they may have found a new treatment for retinitis pigmentosa, a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young adulthood as night blindness or a loss of peripheral vision and in many cases progresses to legal blindness by age 40.

22 Jul 2010

Affymetrix second-quarter total revenue decreases to $71.7 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.

22 Jul 2010

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme Corp. today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year.

21 Jul 2010

New insights on early pathogenic events, strategies for preventing HIV infection

In a plenary lecture at the 18th International AIDS conference in Vienna, Austria, Anthony S. Fauci, M.D., will present new insights on the early and complex pathogenic events that occur rapidly-within hours to days-following sexual exposure to HIV.

21 Jul 2010

Health Canada grants Osiris Priority Review for Prochymal NDS

Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.

21 Jul 2010

Researchers find that increase in leptin may promote colorectal neoplasms

Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.

21 Jul 2010

Spindly extensions of bone cells sense mechanical stimulation and signal release of bone-growth factors

A long-standing question in bone biology has been answered: It is the spindly extensions of bone cells that sense mechanical stimulation and signal the release of bone-growth factors, according to research from The University of Texas Health Science Center at San Antonio.

21 Jul 2010

Study finds sepsis 10 times more common and lethal than heart attacks, blood clots

New research from The Methodist Hospital in Houston shows that sepsis is 10 times more common and more lethal than other more well-known surgical complications including heart attacks and blood clots. These results, published today in the Archives of General Surgery, show a greater need for sepsis awareness and early recognition during and after surgery.

21 Jul 2010

INRA Genomic Platform core facility now provides services on Fluidigm's BioMark System for Genetic Analysis

Fluidigm Corporation today announced that the Toulouse Midi-Pyrénées Genomic Platform - Genotoul INRA core facility is now providing a wide range of services on a BioMark™ System for Genetic Analysis to a wide range of French researchers. These services include SNP genotyping, gene expression analysis and digital PCR quantification of DNA libraries for next-generation sequencing. The INRA has been validating the performance of the system on several projects over the past year.

21 Jul 2010

NT-020 nutrients promote adult neural stem cell growth in aged rats: Researchers

A combination of nutrients called NT-020 promoted adult neural stem cell proliferation in aged rats and boosted their memory performance, reported University of South Florida researchers studying natural therapeutic approaches to promoting the health of neurons in the aging brain.

21 Jul 2010

Researchers block central pathway for prostate cancer progression

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.

21 Jul 2010

Harvard Apparatus/ Hugo Sachs Elektronik business collaborates to develop lung regeneration bioreactor

Harvard Bioscience, Inc., a global developer, manufacturer and marketer of a broad range of specialized products used to advance life science research and regenerative medicine, announces that its Harvard Apparatus / Hugo Sachs Elektronik business collaborated with Dr. Harald Ott and Massachusetts General Hospital (MGH) to design and manufacture a novel bioreactor that was used to grow a functional lung. The lung was subsequently transplanted into a rat.

21 Jul 2010

AHAF enters new partnership with BioMed Central's Molecular Neurodegeneration journal

The American Health Assistance Foundation (AHAF) today announced a new partnership with BioMed Central's open access journal, Molecular Neurodegeneration (MN) in which the publication will be the official open access journal of AHAF.

21 Jul 2010

Depressive symptoms in patients with HCV infection overlooked

Researchers from Denmark, Sweden, Norway and Finland (the NORDynamIC project group) have observed that depressive symptoms in patients with hepatitis C virus (HCV) infection are commonly overlooked in routine clinical interviews, and that treatment-induced depression compromises the outcome of HCV therapy. A second U.S. study found that patients with chronic infection had lower (work) productivity and incurred higher medical benefit costs than those without HCV.

21 Jul 2010

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Researchers from the La Jolla Institute for Allergy & Immunology have joined forces with the Dana-Farber Cancer Institute in Boston and Washington University in St. Louis to investigate a potential new therapy for sickle cell disease, a severe and chronic illness affecting more than 70,000 Americans and several million people worldwide.

21 Jul 2010

Scientists find way to block androgens, halt tumor progression in prostate cancer

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens. Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth.

21 Jul 2010

Mesoblast gains Australian TGA licence to manufacture Mesenchymal Precursor Cell products

Australian regenerative medicine company, Mesoblast Limited, today announced that the Australian Therapeutic Goods Administration (TGA) has issued a licence to Mesoblast to manufacture and supply its proprietary Mesenchymal Precursor Cell (MPC) products.

21 Jul 2010

B Cell News and Research

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Study links application of disinfectants in recreational pools to adverse health outcomes

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Valproic acid halts vision loss in patients with retinitis pigmentosa

Affymetrix second-quarter total revenue decreases to $71.7 million

Genzyme second-quarter revenue decreases to $1.08 billion

New insights on early pathogenic events, strategies for preventing HIV infection

Health Canada grants Osiris Priority Review for Prochymal NDS

Researchers find that increase in leptin may promote colorectal neoplasms

Spindly extensions of bone cells sense mechanical stimulation and signal release of bone-growth factors

Study finds sepsis 10 times more common and lethal than heart attacks, blood clots

INRA Genomic Platform core facility now provides services on Fluidigm's BioMark System for Genetic Analysis

NT-020 nutrients promote adult neural stem cell growth in aged rats: Researchers

Researchers block central pathway for prostate cancer progression

Harvard Apparatus/ Hugo Sachs Elektronik business collaborates to develop lung regeneration bioreactor

AHAF enters new partnership with BioMed Central's Molecular Neurodegeneration journal

Depressive symptoms in patients with HCV infection overlooked

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Scientists find way to block androgens, halt tumor progression in prostate cancer

Mesoblast gains Australian TGA licence to manufacture Mesenchymal Precursor Cell products

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News